Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 16.07
OTCPK:NONOF's Cash to Debt is ranked higher than
75% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. OTCPK:NONOF: 16.07 )
OTCPK:NONOF' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 16.07

Equity to Asset 0.58
OTCPK:NONOF's Equity to Asset is ranked higher than
69% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. OTCPK:NONOF: 0.58 )
OTCPK:NONOF' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.73
Current: 0.58

0.51
0.73
Interest Coverage 572.60
OTCPK:NONOF's Interest Coverage is ranked higher than
61% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OTCPK:NONOF: 572.60 )
OTCPK:NONOF' s 10-Year Interest Coverage Range
Min: 4.79   Max: 572.6
Current: 572.6

4.79
572.6
F-Score: 7
Z-Score: 19.82
M-Score: -2.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 38.15
OTCPK:NONOF's Operating margin (%) is ranked higher than
96% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. OTCPK:NONOF: 38.15 )
OTCPK:NONOF' s 10-Year Operating margin (%) Range
Min: 10.5   Max: 37.77
Current: 38.15

10.5
37.77
Net-margin (%) 30.79
OTCPK:NONOF's Net-margin (%) is ranked higher than
95% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. OTCPK:NONOF: 30.79 )
OTCPK:NONOF' s 10-Year Net-margin (%) Range
Min: 10.59   Max: 30.13
Current: 30.79

10.59
30.13
ROE (%) 69.20
OTCPK:NONOF's ROE (%) is ranked higher than
99% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. OTCPK:NONOF: 69.20 )
OTCPK:NONOF' s 10-Year ROE (%) Range
Min: 11.34   Max: 60.54
Current: 69.2

11.34
60.54
ROA (%) 39.31
OTCPK:NONOF's ROA (%) is ranked higher than
98% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. OTCPK:NONOF: 39.31 )
OTCPK:NONOF' s 10-Year ROA (%) Range
Min: 7.57   Max: 37.03
Current: 39.31

7.57
37.03
ROC (Joel Greenblatt) (%) 129.33
OTCPK:NONOF's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. OTCPK:NONOF: 129.33 )
OTCPK:NONOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.89   Max: 126.76
Current: 129.33

6.89
126.76
Revenue Growth (%) 14.30
OTCPK:NONOF's Revenue Growth (%) is ranked higher than
86% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. OTCPK:NONOF: 14.30 )
OTCPK:NONOF' s 10-Year Revenue Growth (%) Range
Min: -46.2   Max: 127.6
Current: 14.3

-46.2
127.6
EBITDA Growth (%) 19.00
OTCPK:NONOF's EBITDA Growth (%) is ranked higher than
91% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. OTCPK:NONOF: 19.00 )
OTCPK:NONOF' s 10-Year EBITDA Growth (%) Range
Min: -44.6   Max: 130.7
Current: 19

-44.6
130.7
EPS Growth (%) 23.90
OTCPK:NONOF's EPS Growth (%) is ranked higher than
92% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. OTCPK:NONOF: 23.90 )
OTCPK:NONOF' s 10-Year EPS Growth (%) Range
Min: 0.8   Max: 37.2
Current: 23.9

0.8
37.2
» OTCPK:NONOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OTCPK:NONOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.70
NONOF's P/E(ttm) is ranked higher than
93% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 26.70 )
NONOF' s 10-Year P/E(ttm) Range
Min: 12.13   Max: 32.39
Current: 26.7

12.13
32.39
P/B 19.60
NONOF's P/B is ranked higher than
59% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. NONOF: 19.60 )
NONOF' s 10-Year P/B Range
Min: 1.7   Max: 21.13
Current: 19.6

1.7
21.13
P/S 8.20
NONOF's P/S is ranked higher than
82% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.28 vs. NONOF: 8.20 )
NONOF' s 10-Year P/S Range
Min: 2.81   Max: 9.14
Current: 8.2

2.81
9.14
PFCF 34.30
NONOF's PFCF is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 34.30 )
NONOF' s 10-Year PFCF Range
Min: 12.07   Max: 47.01
Current: 34.3

12.07
47.01
EV-to-EBIT 21.92
NONOF's EV-to-EBIT is ranked higher than
94% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 21.92 )
NONOF' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 27
Current: 21.92

9.1
27
PEG 1.20
NONOF's PEG is ranked higher than
99% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 1.20 )
NONOF' s 10-Year PEG Range
Min: 0.12   Max: 1.86
Current: 1.2

0.12
1.86
Shiller P/E 38.90
NONOF's Shiller P/E is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 38.90 )
NONOF' s 10-Year Shiller P/E Range
Min: 18.94   Max: 43.06
Current: 38.9

18.94
43.06
Current Ratio 1.44
NONOF's Current Ratio is ranked higher than
57% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. NONOF: 1.44 )
NONOF' s 10-Year Current Ratio Range
Min: 1.31   Max: 2.88
Current: 1.44

1.31
2.88
Quick Ratio 0.99
NONOF's Quick Ratio is ranked higher than
55% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. NONOF: 0.99 )
NONOF' s 10-Year Quick Ratio Range
Min: 0.92   Max: 2.34
Current: 0.99

0.92
2.34

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.80
NONOF's Dividend Yield is ranked higher than
73% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 1.16 vs. NONOF: 1.80 )
NONOF' s 10-Year Dividend Yield Range
Min: 1.02   Max: 2.47
Current: 1.8

1.02
2.47
Dividend Payout 0.46
NONOF's Dividend Payout is ranked higher than
95% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 0.46 )
NONOF' s 10-Year Dividend Payout Range
Min: 0.51   Max: 1.61
Current: 0.46

0.51
1.61
Dividend growth (3y) 33.90
NONOF's Dividend growth (3y) is ranked higher than
95% of the 80 Companies
in the Global Biotechnology industry.

( Industry Median: 11.10 vs. NONOF: 33.90 )
NONOF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 37.5
Current: 33.9

0
37.5
Yield on cost (5-Year) 5.62
NONOF's Yield on cost (5-Year) is ranked higher than
96% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 1.32 vs. NONOF: 5.62 )
NONOF' s 10-Year Yield on cost (5-Year) Range
Min: 3.01   Max: 7.3
Current: 5.62

3.01
7.3
Share Buyback Rate 2.70
NONOF's Share Buyback Rate is ranked higher than
97% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. NONOF: 2.70 )
NONOF' s 10-Year Share Buyback Rate Range
Min: 49.1   Max: -92.3
Current: 2.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.52
NONOF's Price/Tangible Book is ranked higher than
64% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. NONOF: 20.52 )
NONOF' s 10-Year Price/Tangible Book Range
Min: 1.88   Max: 21.28
Current: 20.52

1.88
21.28
Price/DCF (Projected) 3.56
NONOF's Price/DCF (Projected) is ranked higher than
93% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 3.56 )
NONOF' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 23.73
Current: 3.56

1.3
23.73
Price/Median PS Value 1.75
NONOF's Price/Median PS Value is ranked higher than
74% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. NONOF: 1.75 )
NONOF' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 1.68
Current: 1.75

0.16
1.68
Price/Peter Lynch Fair Value 1.13
NONOF's Price/Peter Lynch Fair Value is ranked higher than
99% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 1.13 )
NONOF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.07   Max: 1.66
Current: 1.13

0.07
1.66
Price/Graham Number 5.02
NONOF's Price/Graham Number is ranked higher than
88% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 5.02 )
NONOF' s 10-Year Price/Graham Number Range
Min: 0.83   Max: 5
Current: 5.02

0.83
5
Earnings Yield (Greenblatt) 4.60
NONOF's Earnings Yield (Greenblatt) is ranked higher than
76% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. NONOF: 4.60 )
NONOF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.7   Max: 11
Current: 4.6

3.7
11
Forward Rate of Return (Yacktman) 24.18
NONOF's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. NONOF: 24.18 )
NONOF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.3   Max: 153.9
Current: 24.18

4.3
153.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:NVO.USA, 0QIU.UK, NOVO B.Denmark, NOVA.Germany, NOVC.Germany
Novo Nordisk is a healthcare company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company operates in two business segments, diabetes care and biopharmaceuticals. The diabetes care segment covers insulin's, GLP-1, other protein-related products and projects such as glucagon and protein-related delivery systems, obesity and oral anti-diabetic drugs. The biopharmaceuticals segment covers the therapy areas of hemophilia, growth hormone therapy, hormone replacement therapy and inflammation. The company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
» More Articles for OTCPK:NONOF

Headlines

Articles On GuruFocus.com
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
GAMCO CIO Howard Ward on Reliable Consumer Stock Ideas Apr 09 2014 
Assessing the New Boss at National Oilwell Varco Mar 31 2014 
Amgen Inc: As Good as It Gets? Feb 20 2014 
Shire PLC: Time to Panic? Feb 07 2014 
Weekly 52-Week Highs Highlight: ACT, NVO, NXPI, WYNN Feb 03 2014 

More From Other Websites
Shire eating disorder drug gets U.S. priority review Sep 15 2014
Novo Nordisk shares rise as US panel backs obesity drug Sep 12 2014
European shares end slightly lower, focus on Fed and Scottish vote Sep 12 2014
European shares tick lower ahead of Fed meet and Scottish vote Sep 12 2014
European shares inch higher, caution before Fed, Scotland vote Sep 12 2014
Europe midday: Stocks little changed ahead of US data Sep 11 2014
Novo Nordisk reports profit rise, progress on US drug permit Aug 07 2014
Gains in healthcare stocks prop up European equities Jun 17 2014
Gains in healthcare stocks prop up European equities Jun 17 2014
Chinese city targets pharma firms in graft crackdown May 27 2014
Novo Nordisk earnings rise, lowers sales forecast May 01 2014
[video] 'Focus' key amid healthcare M&A: Novo Nordisk CFO May 01 2014
FDA approves GSK's Tanzeum to treat type 2 diabetes Apr 15 2014
FDA approves GSK's Tanzeum to treat type 2 diabetes Apr 15 2014
Is Biogen A Value Stock Yet? Apr 15 2014
Status regarding Novo Nordisk's holding of its own shares (31 March 2014) Apr 01 2014
Weight loss surgery helps many reverse type 2 diabetes - study Mar 31 2014
Weight loss surgery helps reverse type 2 diabetes for some -study Mar 31 2014
Trading in Novo Nordisk shares by board members, executives and associated persons on 24 March 2014 Mar 25 2014
Share repurchase programme Mar 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK